We Like Ariad’s Story But See Limited Newsflow, Says UBS’ Andrew Peters


Ariad Pharmaceuticals (ARIA) had its price target reduced by UBS from $7.50 to $7.00 in a research report released this morning. UBS currently has a Neutral rating on the stock.

According to UBS analyst Andrew Peters, the key question on ARIA shares is whether or not lower doses of Iclusig sufficiently mitigate risk of vaso-occlusive events and whether these lower doses are active. While early data have shown hints that an induction-style regimen (eg 45mg initially with 15mg maintenance) could be active, the key unknown is if this new protocol would result in a meaningfully different risk profile. Recent updates at both ASH and ASCO suggest a dose relationship around CV risk is likely, although the bar for an acceptable profile is still unclear and the trend toward risk reduction may be narrowing.

“Following a constructive ASCO meeting which saw multiple updates we see few nearterm drivers of upside risk given high Street expectations for the Iclusig re-launch. We await the announcement of the dosing study but believe actionable data will not be available until 2016, and hence remain Neutral until timing is more attractive”, said the analyst.

ARIA Chart

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts